Tumor necrosis factor alpha (TNFα) blockers, such as adalimumab (ADA), etanercept (ETA), and infliximab (IFX), are playing a significant role in the treatment of autoimmune inflammatory diseases such as rheumatoid arthritis (RA) and spondyloarthritis (SpA). This evidence concerns the gene TNF and spondyloarthropathy.